ThePMD

Off the Wire

Pliaglis® Regulatory Update

FDA Sets PDUFA Date of APRIL 16, 2012
 

Threshold Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results of TH-302

Primary Endpoint Met in Patients With First-Line Advanced Pancreatic Cancer
 

Adeona Becomes Synthetic Biologics, Inc.

New Name Reflects Biotechnology Company Focus on the Emerging Field of Synthetic Biologics
 
 

FDA Approves Gen-Probe's PROGENSA® PCA3 Assay

Test May Help Reduce Unnecessary Repeat Prostate Biopsies
 

Biogen Idec to Acquire Stromedix

Acquisition Complements Biogen Idec's Scientific Expertise and Core Capabilities in Immunology
 

Karo Bio Terminates the Eprotirome Program

Risks Associated with Long Term Use
 

FDA Approves ZIOPTAN™ (tafluprost ophthalmic solution)

Merck's Once-Daily, Preservative-Free Ophthalmic Medication
 

Valeant Pharmaceuticals to Acquire Eyetech

Transaction Expected to Close This Week
 

Columbia Laboratories Transfers NDA for Progesterone Vaginal Gel 8% to Watson Pharmaceuticals

The FDA is Expected to Take Action on the NDA by February 26, 2012